What is the appropriate management for a 78-year-old female with persistent hyponatremia (serum sodium 132 mmol/L) despite a fluid restriction of approximately 32 oz (≈1 L) per day?

Management of Persistent Hyponatremia Despite Fluid Restriction

For this 78-year-old woman with persistent hyponatremia (Na 132 mmol/L) despite 32 oz (≈1 L) daily fluid restriction, escalate to second-line therapy with oral urea (≥30 g/day) as the preferred option, or consider vasopressin receptor antagonists (vaptans) if urea is not tolerated. 1

Why Fluid Restriction Alone Has Failed

• Approximately half of SIADH patients do not respond to fluid restriction as first-line therapy, making this a common clinical scenario. 2
• At a serum sodium of 132 mmol/L with ongoing fluid restriction of 1 L/day (the recommended 1–1.5 L range), this patient has demonstrated fluid restriction-refractory hyponatremia. 1

Second-Line Treatment Options

Oral Urea (Preferred)

• Oral urea at doses ≥30 g/day is safe and effective for fluid restriction-refractory hyponatremia in SIADH. 3
• In a cohort of 78 treatment episodes, 64.1% of patients achieved serum sodium ≥130 mmol/L at 72 hours with urea therapy. 3
• The mean sodium increase with urea (6.9 ± 4.8 mmol/L at 72 hours) was significantly greater than with preceding treatments including fluid restriction (-1.0 ± 4.7 mmol/L; P < 0.001). 3
• No patients developed hypernatremia, overcorrection, or died in this series, and side effects (principally distaste) occurred in only 22.7% without severe events. 3
• Urea is considered very effective and safe by current treatment standards. 2

Vasopressin Receptor Antagonists (Tolvaptan)

• Tolvaptan is an alternative second-line option for euvolemic or hypervolemic hyponatremia when fluid restriction fails. 1
• In a randomized trial, tolvaptan increased serum sodium by 5.7 ± 3.2 mmol/L versus 1.0 ± 4.7 mmol/L with fluid restriction alone (p = 0.0065). 4
• Critical safety requirement: Do not restrict fluids during the first 24 hours of tolvaptan therapy; patients should drink according to thirst to prevent rapid overcorrection. 5
• Check serum sodium every 2–4 hours during tolvaptan initiation to ensure correction rate stays below 8 mmol/L per 24 hours. 5
• Avoid tolvaptan in patients with altered mental status who cannot maintain adequate oral intake, as this increases overcorrection risk. 5

Salt Tablets Plus High-Protein Diet

• Salt tablets (approximately 100 mEq PO three times daily) combined with a high-protein diet represent another second-line option. 1
• This approach increases solute intake and may be particularly useful in patients who can tolerate oral supplementation. 2

Monitoring Strategy

• Check serum sodium every 4 hours initially when starting second-line therapy, then transition to daily monitoring once stable. 1
• Record daily weights and input/output volumes to reassess volume status throughout treatment. 1
• Aim for a correction rate ≤8–10 mmol/L per 24 hours to minimize risk of osmotic demyelination syndrome. 1, 5

Important Caveats

• Verify the diagnosis is truly SIADH by confirming euvolemia on physical examination, urine osmolality >100 mOsm/kg, urine sodium >40 mmol/L, and normal thyroid/adrenal function. 1
• At Na 132 mmol/L with mild or no symptoms, this patient does not require rapid correction with hypertonic saline, which is reserved for severely symptomatic cases (altered mental status, seizures, coma). 1
• Review medications for potential culprits (thiazides, SSRIs, carbamazepine, NSAIDs) that may be contributing to SIADH. 6
• If urea or vaptans are initiated and sodium rises too rapidly (>8 mmol/L in 24 hours), immediately administer hypotonic fluids (5% dextrose in water) to lower serum sodium and prevent osmotic demyelination. 5

Practical Algorithm

1. Confirm fluid restriction failure: Patient on 1 L/day restriction with persistent Na ≤132 mmol/L after adequate trial (typically 3–7 days). 1
2. First choice: Start oral urea ≥30 g/day, monitor sodium every 4 hours initially. 3
3. If urea not tolerated (distaste, nausea): Switch to tolvaptan 10 mg daily, allow free water intake, monitor sodium every 2–4 hours. 5, 4
4. Alternative: Salt tablets 100 mEq TID plus high-protein diet if patient prefers oral supplementation. 1
5. Target: Gradual rise to Na 135–145 mmol/L at rate ≤8 mmol/L per 24 hours. 1, 2